ArticleACS biomaterials science & engineering2026
Synergistic Neuroprotection in Parkinson's Disease via Photobiomodulation and Liposomal Rosmarinic Acid Delivery.
Article in ACS biomaterials science & engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss, oxidative stress, and mitochondrial dysfunction. Current treatment strategies are largely symptomatic and fail to halt disease progression. This research work explores a novel dual-modal therapeutic strategy combining Photobiomodulation (PBM) using near-infrared (NIR) light with nanotechnology-enhanced delivery of Rosmarinic Acid (RA) for the treatment of PD. Building upon the findings of previous works, which established the neuroprotective potential of RA, this study extends its application to PD treatment through the development of RA-loaded liposomes (RA@LP) and their integration with NIR-induced PBM. As a noninvasive modality, NIR light has demonstrated efficacy in stimulating mitochondrial activity, promoting ATP production, and reducing oxidative stress through PBM mechanisms. In parallel, RA, a potent natural antioxidant, has been encapsulated within liposomal nanocarriers to enhance its stability, bioavailability, and targeted delivery to affected neuronal tissues. The combined therapeutic platform of PBM and RA@LP is designed to eliminate endogenous and exogenous reactive oxygen species (ROS), thereby breaking the self-perpetuating cycle of oxidative stress and mitochondrial damage underlying PD pathogenesis. We highlight
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.